

Leukemia Acute Graft Versus Host Disease

**Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A  
in Combination With Standard of Care in Participants Undergoing  
Allogeneic Hematopoietic Stem Cell Transplantation**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04539470 GA41825

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Efmarodocokin Alfa and to make a preliminary assessment of activity of Efmarodocokin Alfa in combination with standard-of-care (SOC) in the prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

**NCT04539470 GA41825**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No